Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib combinations in advanced solid tumors
NCT02586987Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selumetinib in solid tumor (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability by assessment of Adverse Events, Safety and tolerability by assessment of safety laboratory tests and 5 more. Started Dec 2015; status: completed.
02
Drugs
selumetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02586987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586987.